TURCO, FABIO
 Distribuzione geografica
Continente #
NA - Nord America 425
EU - Europa 308
AS - Asia 150
OC - Oceania 6
AF - Africa 4
SA - Sud America 1
Totale 894
Nazione #
US - Stati Uniti d'America 408
IT - Italia 110
IE - Irlanda 78
CN - Cina 41
SE - Svezia 38
GB - Regno Unito 20
HK - Hong Kong 20
SG - Singapore 19
IN - India 17
CA - Canada 14
IR - Iran 13
JP - Giappone 12
ES - Italia 11
BE - Belgio 7
CH - Svizzera 7
TR - Turchia 7
DE - Germania 6
FI - Finlandia 6
NL - Olanda 6
PH - Filippine 6
PL - Polonia 6
AU - Australia 5
FR - Francia 5
KR - Corea 5
CZ - Repubblica Ceca 4
NG - Nigeria 4
MO - Macao, regione amministrativa speciale della Cina 3
MX - Messico 3
MY - Malesia 3
HU - Ungheria 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
BO - Bolivia 1
HR - Croazia 1
NZ - Nuova Zelanda 1
TH - Thailandia 1
UA - Ucraina 1
Totale 894
Città #
Chandler 113
Dublin 78
Turin 42
Nyköping 34
Singapore 13
Ashburn 11
Hong Kong 11
Milan 10
Genoa 9
London 9
Medford 9
New York 9
Princeton 9
Hangzhou 8
Seattle 8
Los Angeles 7
Tokyo 7
Torino 6
Hyderabad 5
Isfahan 5
Lappeenranta 5
Madrid 5
Abuja 4
Beijing 4
Chennai 4
La Quinta 4
Molenbeek-Saint-Jean 4
Moncalieri 4
Montreal 4
Seoul 4
Ankara 3
Chengdu 3
Chicago 3
Coventry 3
Dagupan 3
Fairfield 3
Frankfurt am Main 3
Guangzhou 3
Guwahati 3
Hebei 3
Liverpool 3
Macao 3
Nanaimo 3
Petaling Jaya 3
Rutherford 3
Sydney 3
Vezia 3
Wilmington 3
Barletta 2
Buffalo 2
Changsha 2
Croydon 2
Dalian 2
Davao City 2
Devrek 2
Dong Ket 2
Edmonton 2
Ferrol 2
Gdynia 2
Germantown 2
Ghent 2
Guadalajara 2
Guadix 2
Guiyang 2
Hawthorne 2
Hoover 2
Hradec Králové 2
Istanbul 2
Johnston 2
Kolkata 2
Krakow 2
Leipzig 2
Maastricht 2
Maniowy 2
Marseille 2
Milwaukee 2
Nagytarcsa 2
New Delhi 2
Nijmegen 2
Omaha 2
Paris 2
Pierrefonds 2
Redmond 2
San Marcos 2
Toronto 2
Trento 2
Vigo 2
Virginia Beach 2
Wuhan 2
Zurich 2
Adelaide 1
Alessandria 1
Amsterdam 1
Ann Arbor 1
Anqing 1
Auckland 1
Austin 1
Bainbridge Island 1
Bellinzona 1
Birmingham 1
Totale 593
Nome #
Renal cell carcinoma (RCC): Fatter is better? A review on the role of obesity in RCC 201
Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate 77
Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside 53
Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives 47
Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs 40
Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis 39
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with Abiraterone or Enzalutamide 38
Prognostic factors in metastatic castration resistant prostate cancer patients treated with Radium-223: a retrospective study 37
Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report 37
New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine? 32
Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine? 30
Prognostic role of early PSa drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide 30
Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications 29
Therapeutic sequencing in advanced renal cell carcinoma: how to choose considering clinical and biological factors 27
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16) 26
Darolutamide in Metastatic Prostate Cancer 26
Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy 25
New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond 23
Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough? 23
How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy? 18
Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients-An Italian Single-Center Experience 16
How Does Environmental and Occupational Exposure Contribute to Carcinogenesis in Genitourinary and Lung Cancers? 14
Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis 8
Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma 7
Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study 6
Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer 6
Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study 5
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis 5
Safety profile of darolutamide versus placebo: a systematic review and meta-analysis 2
Totale 927
Categoria #
all - tutte 5.335
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.335


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202111 0 0 0 0 0 0 1 1 3 1 2 3
2021/2022103 12 2 5 1 4 0 2 0 6 8 38 25
2022/2023534 30 51 15 27 49 104 40 45 61 39 35 38
2023/2024279 36 48 21 38 11 28 22 14 9 36 16 0
Totale 927